摘要
Abstract
Objective:To observe the efficacy of intravenous human immunoglobulin as an adjuvant treatment for neonatal pneumonia and its influence on inflammatory response.Method:According to the random number table method,86 children with pneumonia admitted to Putian Children's Hospital from June 2022 to October 2024 were divided into two groups,with 43 cases in each group.The control group received conventional treatment.On this basis,the observation group was intravenously injected with human immunoglobulin as an adjuvant treatment for 7 days.The therapeutic effects,symptom improvement time,inflammatory factors[white blood cell count(WBC),procalcitonin(PCT),C-reactive protein(CRP)]and adverse reactions of the two groups were compared.Result:After treatment,compared with the control group,the observation group had a higher total effective rate,fever reduction,cough disappearance,shorter hospital stay,and lower levels of serum WBC,PCT and CRP.The differences were statistically significant(P<0.05).There was no statistically significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion:Intravenous human immunoglobulin as an adjuvant therapy can improve the clinical efficacy of children with neonatal pneumonia,reduce inflammatory responses,promote the recovery process,shorten the length of hospital stay,and has high safety.关键词
新生儿肺炎/人免疫球蛋白/疗效/炎症反应Key words
Neonatal pneumonia/Human immunoglobulin/Efficacy/Inflammatory response
